Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
doi: 10.1111/epi.18492 46 AmbroginiPTorquatoPBartoliniDAlbertiniMCLattanziDDi PalmaMet al
Last reviewed: June 1, 2026 Last updated: June 1, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
No denied claims
2024 Sales (USD): $13.42 billion Why it sold so well: Gilead Sciences flagship HIV treatment, Biktarvy, had exceptional growth in 2024, with global sales increasing 13% year-over-year to $13.4 billion
US$ 21.75
US$ 23.92
US$ 24.90
US$ 28.11
US$ 29.23
